Advertisement

Parasitology Research

, Volume 118, Issue 12, pp 3399–3408 | Cite as

Assessment of the potential therapeutic effects of omeprazole in Schistosoma mansoni infected mice

  • Asmaa R. Ellakany
  • Dina I. ElgendyEmail author
  • Hanan A. Alshenawy
  • Amira E. Abdel Ghaffar
Helminthology - Original Paper
  • 100 Downloads

Abstract

Schistosomiasis is a neglected chronic parasitic disease with a significant lasting morbidity. Currently, praziquantel (PZQ) is the most efficient drug for schistosomiasis worldwide. However, the possibility of the occurrence of resistance to PZQ is increasing. Therefore, there is a vital need to find new antischistosomal drugs or to increase the efficacy of the existing ones. Omeprazole is a proton pump inhibitor which is reported to have antiparasitic properties. Thus, the aim of this study was to assess the potential therapeutic effects of omeprazole in experimental Schistosoma mansoni infection either alone or in combination with PZQ. For this aim, 80 laboratory bred mice were divided into 3 groups; uninfected control, infected untreated control, and infected and treated at tenth week P.I. The last group was divided into three subgroups that received either PZQ alone, omeprazole alone, or both drugs. The effectiveness of treatment was assessed by adult worm counts, liver egg count, scanning electron microscopy of adult worms, histopathological, and immunohistochemical (GFAP) examination. There was significant reduction of adult worm counts, liver egg counts, size, diameter of hepatic granulomas, hepatic fibrosis, and GFAP expression in the group that received combined treatment as compared to PZQ group. Moreover, the tegumental changes were more evident in the group that received combined treatment. In conclusion, the administration of omeprazole with PZQ improved the efficacy of PZQ in the treatment of Schistosomiasis mansoni.

Keywords

Schistosoma mansoni Omeprazole Scanning electron microscopy (SEM) Hepatic fibrosis Glial fibrillary acidic protein (GFAP) 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Abuhelwa AY, Mudge S, Upton RN, Foster DJR (2018) Mechanistic assessment of the effect of omeprazole on the in vivo pharmacokinetics of itraconazole in healthy volunteers. Eur J Drug Metab Pharmacokinet 44(2):201–215 1–15Google Scholar
  2. Ajibola O, Gulumbe BH, Eze AA, Obishakin E (2018) Tools for detection of schistosomiasis in resource limited settings. Med Sci 6(2):39–50Google Scholar
  3. Almeida GT, Lage RCG, Anderson L, Venancio TM, Nakaya HI, Miyasato PA, Rofatto HK, Zerlotini A, Nakano E, Oliveira G, Verjovski-Almeida S (2015) Synergy of omeprazole and praziquantel in vitro treatment against Schistosoma mansoni adult worms. PLoS Negl Trop Dis 9(9):4086–4108Google Scholar
  4. Al-Olayan EM, El-Khadragy MF, Aref AM, Othman MS, Kassab RB, Abdel Moneim AE (2014) The potential protective effect of Physalis peruviana L. against carbon tetrachloride-induced hepatotoxicity in rats is mediated by suppression of oxidative stress and downregulation of MMP-9 expression. Oxidative Med Cell Longev 2014:381413Google Scholar
  5. Amara RO, Ramadan AA, El-Moslemany RM, Eissa MM, El-Azzouni MZ, El-Khordagui LK (2018) Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential Schistosoma mansoni tegumental targeting. Int J Nanomedicine 13:4493–4505PubMedPubMedCentralGoogle Scholar
  6. Andrade ZA (2009) Schistosomiasis and liver fibrosis. Parasite Immunol 31:656–663PubMedGoogle Scholar
  7. Bancroft JD, Steven A (1975) Histopathological stains and their diagnostic uses, 1st edn. Churchill Livingstone, New York, pp 1–20Google Scholar
  8. Bartley PB, Ramm GA, Jones MK, Ruddel RG, Li Y, McManus DP (2006) A contributory role for activated hepatic stellate cells in the dynamics of Schistosoma japonicum egg-induced fibrosis. Int J Parasitol 36(9):993–1001PubMedGoogle Scholar
  9. Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK (2003) A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem 278(13):10993–11001PubMedGoogle Scholar
  10. Carotti S, Morini S, Corradini SG, Burza MA, Molinaro A, Carpino G, Merli M, De Santis A, Muda AO, Rossi M, Attili AF, Gaudio E (2008) Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transpl 14(6):806–814PubMedGoogle Scholar
  11. Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T (2002) Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 36:200–209PubMedGoogle Scholar
  12. Cheever AW (1968) Conditions affecting the accuracy of potassium hydroxide digestion in techniques for counting Schistosoma mansoni eggs in tissues. Bull World Health Organ 39:328–331PubMedPubMedCentralGoogle Scholar
  13. Cioli D, Pica-Mattoccia L, Basso A, Guidi A (2014) Schistosomiasis control: Praziquantel forever? Mol Biochem Parasitol 195(1):23–29PubMedGoogle Scholar
  14. Crellen T, Walker M, Lamberton PH, Kabatereine NB, Tukahebwa EM, Cotton JA, Webster JP (2016) Reduced efficacy of praziquantel against Schistosoma mansoni is associated with multiple rounds of mass drug administration. Clin Infect Dis 63(9):1151–1159PubMedPubMedCentralGoogle Scholar
  15. de Oliveira RN, Rehder VLG, Oliveira ASS, Júnior ÍM, de Carvalho JE, de Ruiz AL, Jeraldo VL, Linhares AX, Allegretti SM (2012) Schistosoma mansoni: in vitro schistosomicidal activity of essential oil of Baccharis trimera (Less) DC. Exp Parasitol 132(2):135–143PubMedGoogle Scholar
  16. Duvall RH, De Witt WB (1967) An improved perfusion technique for recovering adult schistosomes from laboratory animals. Am J Trop Med Hyg 16:483–486PubMedGoogle Scholar
  17. Elhenawy AA, Ashour RH, Nabih N, Shalaby NM, Megahed N (2017) Possible antifibrotic effect of GDC-0449 (Vismodegib), a hedgehog-pathway inhibitor, in mice model of Schistosoma–induced liver fibrosis. Parasitol Int 66:545–554PubMedGoogle Scholar
  18. El-Lakkany N, Nosseir M (2007) Pharcodynamics of pentoxifylline and /or praziquantel in murine schistosomiasis mansoni. APMJS. 115:184–194Google Scholar
  19. El-Shabasy EA, Reda ES, Abdeen SH, Said AE, Ouhtit A (2015) Transmission electron microscopic observations on ultrastructural alterations in Schistosoma mansoni adult worms recovered from C57BL/6 mice treated with radiation attenuated vaccine and/or praziquantel in addition to passive immunization with normal and vaccinated rabbit sera against infection. Parasitol Res 114(4):1563–1580PubMedGoogle Scholar
  20. Garba A, Tohon Z, Sidiki A, Chippaux JP, de Chabalier F (2001) Efficacity of praziquantel in school-aged children in a hyperendemic zone for Schistoma haematobium (Niger, 1999). Bull Soc Pathol Exot 94(1):42–45PubMedGoogle Scholar
  21. Ghebre YT, Raghu G (2016) Idiopathic pulmonary fibrosis: novel concepts of proton pump inhibitors as antifibrotic drugs. Am J Respir Crit Care Med 193:1345–1352PubMedPubMedCentralGoogle Scholar
  22. Ghebremariam YT, Cooke JP, Gerhart W, Griego C, Brower JB, Doyle-Eisele M, Moeller BC, Zhou Q, Ho L, de Andrade J, Raghu G, Peterson L, Rivera A, Rosen GD (2015) Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. J Transl Med 13:249–268PubMedPubMedCentralGoogle Scholar
  23. Gibelli NE, Tannuri U, and Mello ES (2008) Immunohistochemical studies of stellate cells in experimental cholestasis in newborn and adult rats. Clinics (Sao Paulo) 63(5):689–694PubMedPubMedCentralGoogle Scholar
  24. Gouveia MJ, Brindley PJ, Gärtner F, da Costa JMC, Vale N (2018) Drug repurposing for schistosomiasis: combinations of drugs or biomolecules. Pharmaceuticals 11(1):15PubMedCentralGoogle Scholar
  25. Holanda JC, Pellegrino J, Gazzinelli G (1974) Infection of mice with cercariae and schistosomula of Schistosoma mansoni by intravenous and subcutaneous routes. Rev Inst Med Trop 16:132–134Google Scholar
  26. Jacobs W, Bogers J, Deelder A, Wéry M, Van Marck E (1997) Adult Schistosoma mansoni worms positively modulate soluble egg antigen-induced inflammatory hepatic granuloma formation in vivo. Stereological analysis and immunophenotyping of extracellular matrix proteins, adhesion molecules, and chemokines. Am J Pathol 150(6):2033–2045PubMedPubMedCentralGoogle Scholar
  27. Kamel ROA, Bayaumy FE-ZA (2017) Ultrastructural alterations in Schistosoma mansoni juvenile and adult male worms after in vitro incubation with primaquine. Mem Inst Oswaldo Cruz 112(4):247–254PubMedPubMedCentralGoogle Scholar
  28. Kasinathan RS, Sharma LK, Cunningham C, Webb TR, Greenberg RM (2014) Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to Praziquantel. PLoS Negl Trop Dis 8:e3265PubMedPubMedCentralGoogle Scholar
  29. Kedika RR, Souza RF, Spechler SJ (2009) Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 54(11):2312–2317PubMedPubMedCentralGoogle Scholar
  30. Kochar DK, Saini G, Kochar SK, Bumb RA, Mehta RD, Sirohi P, Purohit SK (2006) A double blind randomized placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis. J Vector Borne Dis 43(4):161–167PubMedGoogle Scholar
  31. Kovač J, Vargas M, Keiser J (2017) In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium. Parasit Vectors 10(1):365–369PubMedPubMedCentralGoogle Scholar
  32. Liu J, Giri BR, Chen Y, Luo R, Xia T, Grevelding CG, Cheng G (2018) Schistosoma japonicum IAP and Teg20 safeguard tegumental integrity by inhibiting cellular apoptosis. PLoS Negl Trop Dis 12(7):e0006654PubMedPubMedCentralGoogle Scholar
  33. Lundell L (2015) The physiological background behind and course of development of the first proton pump inhibitor. Scand J Gastroenterol 50(6):680–684PubMedGoogle Scholar
  34. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN (2018) Schistosomiasis. Nat Rev Dis Primers 4(1):13–31PubMedGoogle Scholar
  35. Namazi MR, Jowkar F (2008) A succinct review of the general and immunological pharmacologic effects of proton pump inhibitors. J Clin Pharm Ther 33:215–217PubMedGoogle Scholar
  36. Nelson C, Lee J, Ko K, Sikora AG, Bonnen MD, Enkhbaatar P, Ghebre YT (2017) Therapeutic efficacy of esomeprazole in cotton smoke-induced lung injury model. Front Immunol 8:16Google Scholar
  37. Othman AA, Soliman RH (2015) Schistosomiasis in Egypt: a never-ending story? Acta Trop 148:179–190PubMedGoogle Scholar
  38. Othman AA, Shoheib ZS, Abdel-Aleem GA, Shareef MM (2008) Experimental schistosomal hepatitis: protective effect of coenzyme-Q10 against the state of oxidative stress. Exp Parasitol 120:147–155PubMedGoogle Scholar
  39. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF (2001) Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedeberg's Arch Pharmacol 364:551–557Google Scholar
  40. Pearce EJ (2005) Priming of the immune response by Schistosome eggs. Parasite Immunol 27:265–270PubMedGoogle Scholar
  41. Pérez-Villanueva J, Romo-Mancillas A, Hernández-Campos A, Yépez-Mulia L, Hernández-Luis F, Castillo R (2011) Antiprotozoal activity of proton-pump inhibitors. Bioorg Med Chem Lett 21(24):7351–7354PubMedGoogle Scholar
  42. Reyes-Vivas H, Mora I, Castillo-Villanueva A, Yépez-Mulia L, Hernández-Alcántara G, Figueroa-Salazar R, García-Torres I, Gómez-Manzo S, Méndez ST, Vanoye-Carlo A, Marcial-Quino J, Torres-Arroyo A, Oria-Hernández J, Gutiérrez-Castrellón P, Enríquez-Flores S, López-Velázquez G (2014) Giardial triosephosphate isomerase as possible target of the cytotoxic effect of omeprazole in Giardia lamblia. Antimicrob Agents Chemother 58(12):7072–7082PubMedPubMedCentralGoogle Scholar
  43. Riel MA, Kyle DE, Bhattacharjee AK, Milhous WK (2002) Efficacy of proton pump inhibitor drugs against Plasmodium falciparum in vitro and their probable pharmacophores. Antimicrob Agents Chemother 46:2627–2632PubMedPubMedCentralGoogle Scholar
  44. Russo MW, Firpi RJ, Nelson DR, Schoonhoven R, Shrestha R, Fried MW (2005) Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C. Liver Transpl 11(10):1235–1241PubMedGoogle Scholar
  45. Tanigawa T, Watanabe T, Higuchi K, Machida H, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Arakawa T (2009) Lansoprazole, a proton pump inhibitor, suppresses production of tumor necrosis factor-alpha and interleukin-1beta induced by lipopolysaccharide and Helicobacter pylori bacterial components in human monocytic cells via inhibition of activation of nuclear factor-kappaB and extracellular signal-regulated kinase. J Clin Biochem Nutr 45(1):86–92PubMedPubMedCentralGoogle Scholar
  46. Targownik LE, Metge C, Roos L, Leung S (2007) The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use. Am J Gastroenterol 102(5):942–950PubMedGoogle Scholar
  47. Tian A, Xu T, Liu K, Zou Q, Yan X (2014) Anti-Helicobacter pylori effect of total alkaloids of sophora alopecuroides in vivo. Chin Med J 127(13):2484–2491PubMedGoogle Scholar
  48. Wang BB, Cheng JY, Gao HH, Zhang Y, Chen ZN, Bian H (2010) Hepatic stellate cells in inflammation-fibrosis-carcinoma axis. Anat Rec 293(9):1492–1496Google Scholar
  49. Weerakoon KG, Gobert GN, Cai P, McManus DP (2015) Advances in the diagnosis of human schistosomiasis. Clin Microbiol Rev 28(4):939–967PubMedPubMedCentralGoogle Scholar
  50. Xavier AML, Magalhães JAS, Cunha GDP, Silva AC, Tavares DAG, Sarro-Silva MD (2010) Morphological tegument alterations of adult Schistosoma mansoni harbored in non antihelminthic treated, high-immune-tolerogenic and low-inflammatory mice. Acta Trop 116(1):95–99PubMedGoogle Scholar
  51. Xiao SH, Shen BG, Chollet J, Tanner M (2000) Tegumental changes in 21 day-old Schistosoma mansoni harboured in mice treated with artemether. Acta Trop 75(3):341–348PubMedGoogle Scholar
  52. Yang JJ, Boissier J, Chen JL, Yao H, Yang S, Rognon A, Qiao C (2015) Design, synthesis and biological evaluation of praziquantel and endoperoxide conjugates as antischistosomal agents. Future Med Chem 7(6):713–725PubMedGoogle Scholar
  53. Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F and Moayyedi P (2013): Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev, (12):CD008337.Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Medical Parasitology Department, Faculty of MedicineTanta UniversityTantaEgypt
  2. 2.Pathology Department, Faculty of MedicineTanta UniversityTantaEgypt

Personalised recommendations